Effects of latanoprost and dipivefrin, alone or combined, on intraocular pressure and on blood-aqueous barrier permeability

British Journal of Ophthalmology

Volumn 82, Issue 4, 1998, Pages 404-406

  Widengard I ^a   Maepea O ^a   Alm, A ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGLAUCOMA AGENT; DIPIVEFRINE; LATANOPROST;

ADULT; AGED; ARTICLE; BLOOD EYE BARRIER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; MALE; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TOPICAL DRUG ADMINISTRATION;

EID: 0031966409     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.82.4.404     Document Type: Article

References (22)

1. Stjernschantz J, Resul B. Phenyl-substituted prostaglandin analogs for glaucoma treatment. Drugs Future 1992; 17:691-704.
2. Resul B, Stjernschantz J, No K, et al. Phenyl-substituted prostaglandins: potent and selective antiglaucoma agents. J Med Chem 1993;36:243-8.
3. Alm A, Stjernschantz J, the Swedish Latanoprost Study Group. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily evening or morning. A comparison with timolol. Ophthalmology 1995;102:1743-52.
4. Camras CB, the United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma. A six-month, masked, multicenter trial in the United States. Ophthalmology 1996; 103:138-47.
5. Watson P, Stjernschantz J, the Latanoprost Study Group. A six-month randomised, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology 1996;103:126-37.
6. Mishima HK, Masuda K, Kitazawa Y, Azuma I, Araie M. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12 week study. Arch Ophthalmol 1996;114:929-32.
7. Camras CB, Feldman SG, Podos SM, et al. Inhibitors of the epinephrine-induced reduction of intraocular pressure by systemic indomethacin in humans. Am J Ophthalmol 1985; 100:169-75.
8. Anderson L, Wilson WS. Inhibition of indomethacin of the increased facility of outflow induced by adrenaline. Exp Eye Res 1990;50:119-26.
9. Camras CB, Bito LZ, Eakins KE. Reduction of intraocular pressure by prostaglandins applied topically to the eyes of conscious rabbits. Invest Ophthalmol Vis Sci 1977;16:1125-34.
10. Bito LZ, Draga A, Blanco J, Camras CB. Long-term maintenance of reduced intraocular pressure by daily or twice daily topical application of prostaglandins to cat or rhesus monkey eyes. Invest Ophthalmol Vis Sci 1983;24:312-9.
11. 2 analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol 1993;111: 1351-8.
12. 2α-isopropyl ester analogues for glaucoma treatment. Jpn J Ophthalmol 1993; 37:259-69.
13. Bartels SP, Pawlowski AM. Chronic electrical stimulation of sympathetic nerves: effects on blood-aqueous barrier. Curr Eye Res 1990;9:927-34.
14. Miyake K, Miyake Y, Kuratomi R. Long-term effects of topically applied epinephrine on the blood-aqueous barrier in humans. Arch Ophthalmol 1987;105:1360-63.
15. Araie M, Mori M, Oshika T. Effect of topical phenylephrine on the permeability of the blood-aqueous barrier in man. Graefes Arch Clin Exp Ophthalmol 1992;230:171-4.
16. Alm A, Villumsen J, Tornquist P, et al. Intraocular pressure reducing effect of PhXA41 in ocular hypertensive agents - a one-month study. Ophthalmology 1993;100: 1312-7.
17. Becker B. Additive effect of epinephrine and acetazolamide in control of intraocular pressure. Am J Ophthalmol 1958;75:639-42.
18. Parrow KA, Hong YJ, Shin DH, Shi DX, McCarty B. Is it worthwhile to add dipivefrin HCl 0.1% to topical beta-1-, beta-2-blocker therapy? Ophthalmology 1989;96:1338-42.
19. Morrison JC, Robin AL. Adjunctive glaucoma therapy. A comparison of apraclonidine to dipivefrin when added to timolol maleate. Ophthalmology 1989;96:3-7.
20. Brounley DW. A comparison of pilocarpine hydrochloride and epinehrine bitartrate. Ann Ophthalmol 1971;3:970-3.
21. Mori M, Sakurai M, Araie M. Effect of topical epinephrine on permeability of blood-aqueous barrier in human eyes. Jpn J Ophthalmol 1992;36:342-7.
22. 2 receptor subtype. Invest Ophthalmol Vis Sci 1990;31:2463-6.